A double-blind randomized placebo-controlled study of the efficacy of the combined treatment with naltrexone and guanfacine for relapse prevention in opiate dependence

Krupitskiĭ E.M.

Sankt-Peterburgskiĭ nauchno-issledovatel'skiĭ psikhonevrologicheskiĭ institut im. V.M. Bekhtereva

Blokhina E.A.

Sankt-Peterburgskiĭ gosudarstvennyĭ meditsinskiĭ universitet im. akad. I.P. Pavlova

Zvartau É.É.

Sankt-Peterburgskiĭ gosudarstvennyĭ meditsinskiĭ universitet im. I.P. Pavlova;
Sankt-Peterburgskiĭ nauchno-issledovatel'skiĭ psikhonevrologicheskiĭ institut im. V.M. Bekhtereva;
fakul'tet psikhiatrii Universiteta shtata Pensil'vaniia (SShA)

Verbitskaia E.V.

Bushara N.М.

Pavlov First St. Petersburg State Medical University, St. Petersburg

Tyurina A.A.

Obstetrics and Gynecology Department Two, Bashkir State Medical University, Ufa, Russia

Palatkin V.Ya.

Pavlov First St. Petersburg State Medical University, St. Petersburg

Yaroslavtseva Т.S.

Pavlov First St. Petersburg State Medical University, St. Petersburg

Burakov A.M.

Masalov D.V.

Romanova T.N.

Grinenko A.Ia.

Sinha R.

Yale University, Department of Psychiatry, New Haven, USA

Kosten Т.

Baylor College of Medicine, Houston, USA

A double-blind randomized placebo-controlled study of the efficacy of the combined treatment with naltrexone and guanfacine for relapse prevention in opiate dependence

Authors:

Krupitskiĭ E.M., Blokhina E.A., Zvartau É.É., Verbitskaia E.V., Bushara N.М., Tyurina A.A., Palatkin V.Ya., Yaroslavtseva Т.S., Burakov A.M., Masalov D.V., Romanova T.N., Grinenko A.Ia., Sinha R., Kosten Т.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2015;115(10): 39‑46

DOI: 10.17116/jnevro201511510139-46

Downloaded: 231

Download PDF (RU)

Contact the author

Table of contents

To cite this article:

Krupitskiĭ EM, Blokhina EA, Zvartau ÉÉ, et al. . A double-blind randomized placebo-controlled study of the efficacy of the combined treatment with naltrexone and guanfacine for relapse prevention in opiate dependence. S.S. Korsakov Journal of Neurology and Psychiatry. 2015;115(10):39‑46. (In Russ.)
https://doi.org/10.17116/jnevro201511510139-46

Подписка 2025-2 (S.S. Korsakov Journal of Neurology and Psychiatry)

Close metadata

Recommended articles:

Pharmacotherapy of schizophrenia: clinical and some age-related aspects. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(7):41-50

To study the effectiveness and impact on the quality of life of patients with subclinical and clinically pronounced anxiety disorder of a mobile application in combination with Adaptol therapy. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(7):98-105

Genetic variants associated with the development of stress disorders: A systematic review of GWAS. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(3):12-26

Stress and obesity relationship. Russian Journal of Preventive Medicine. 2024;(5):123-127

Arterial hypertension in patients — military fighting participants. Russian Journal of Preventive Medicine. 2024;(5):128-132

Level of students’ stress depending on their behavioral characteristics. Russian Journal of Preventive Medicine. 2024;(9):67-74

The relationship between neighborhood infrastructure and stress levels in students. Russian Journal of Preventive Medicine. 2024;(11):70-76

Treatment of acute postoperative pain and prevention of chronic postoperative pain syndrome. Pirogov Russian Journal of Surgery. 2024;(12):81-86

Atopic dermatitis and skin toxic reactions: comparative characteristics, psychosomatic aspects and patient management tactics. Russian Journal of Clinical Dermatology and Venereology. 2024;(6):744-752

Impact of the COVID-19 epidemic on students’ health. Part II. Features of hemodynamics, vegetative regulation, results of psychological and stress resistance testing among students depending on the COVID-19 presence in their medical history. Russian Journal of Preventive Medicine. 2025;(4):94-101

Objective. Authors studied the effect of α-2-adrenoreceptor agonist guanfacine on replace prevention in opiate addicts. Material and methods. Three hundred and one recently detoxified opiate addicts were randomized under the double-blind double-dummy conditions into one of four treatment groups: naltrexone 50 mg/day + guanfacine 1 mg/day (N+G), naltrexone + guanfacine placebo (N+GP), naltrexone placebo + guanfacine (NP+G), and double placebo (NP+GP). The primary outcome was retention in treatment. The secondary outcomes were perceived stress (Perceived Stress Scale) and craving. Results. At the end of six months, 20 (26.7%) patients in the N+G group and 15 (19.7%) (p=0.26 to N+G) in N+GP group were retained in treatment compared to 5 (6.7%) in the NP+G group (p=0.002 to N+G group and p=0.017 to N+GP group) and 8 (10.7%) in the double placebo group (p=0.013 to N+G group). There is no significant difference in retention between the N+G group and N+GP group at the end of treatment. Conclusion. Guanfacine had significant craving and stress reducing effect. Naltrexone was more effective than placebo for relapse prevention in opioid dependent patients. The efficacy of the combination of naltrexone and guanfacine was comparable to naltrexone alone. Guanfacine moderately reduced both stress and craving.

Keywords:

naltrexone

guanfacine

opiate dependence

pharmacotherapy

stress

Authors:

Krupitskiĭ E.M.

Sankt-Peterburgskiĭ nauchno-issledovatel'skiĭ psikhonevrologicheskiĭ institut im. V.M. Bekhtereva

Blokhina E.A.

Sankt-Peterburgskiĭ gosudarstvennyĭ meditsinskiĭ universitet im. akad. I.P. Pavlova

Zvartau É.É.

Verbitskaia E.V.

Bushara N.М.

Pavlov First St. Petersburg State Medical University, St. Petersburg

Tyurina A.A.

Obstetrics and Gynecology Department Two, Bashkir State Medical University, Ufa, Russia

Palatkin V.Ya.

Pavlov First St. Petersburg State Medical University, St. Petersburg

Yaroslavtseva Т.S.

Pavlov First St. Petersburg State Medical University, St. Petersburg

Burakov A.M.

Masalov D.V.

Romanova T.N.

Grinenko A.Ia.

Sinha R.

Yale University, Department of Psychiatry, New Haven, USA

Kosten Т.

Baylor College of Medicine, Houston, USA

Close metadata